Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Effects of Extended Cannabis Abstinence on Mitochondrial Dysfunction in People With Co-Occurring Major Depressive Disorder and Cannabis Use Disorder

EF 2025-26

Résumé
Since recreational cannabis use was legalized in 2018, its prevalence among people with major depressive disorder (MDD) has risen, despite evidence that cannabis may worsen depression outcomes. Previous research from our laboratory has shown that 28 days of biochemically verified cannabis abstinence improves depressive and select neurocognitive symptoms in co-occurring MDD and cannabis use disorder (CUD); however, the mechanisms underlying this relationship are unclear. Recently, mitochondrial dysfunction has been implicated in depression, with evidence of elevated circulating cell-free mitochondrial DNA (ccf-mtDNA) in MDD. Mitochondria play critical roles in neurotransmission, mood, and cognition, and their disruption may worsen depressive symptoms. Critically, cannabis is also believed to impair mitochondrial function, yet little is known about the effects of cannabis on mitochondria in MDD. To address this gap, the proposed study will investigate the effects of extended cannabis abstinence on mitochondrial function in individuals with co-occurring MDD and CUD. Participants will undergo 28 days of cannabis abstinence, confirmed by self-report with biochemical verification. Mitochondrial health will be assessed weekly during the 28-day abstinence period via urine analysis of ccf-mtDNA levels. Depressive and cognitive symptoms will also be measured throughout abstinence. We predict cannabis abstinence (compared to continued use) will result in improved mitochondrial function, as indicated by reduced urinary ccf-mtDNA levels, which will positively correlate with changes in depressive symptoms. Our findings will provide key insight into the biochemical links between depression and cannabis use and may identify new targets for the treatment of co-occurring MDD and CUD.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572590
Name
Lonnee Eryn P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effects of Extended Cannabis Abstinence on Mitochondrial Dysfunction in People With Co-Occurring Major Depressive Disorder and Cannabis Use Disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Biochemistry; Cannabis; Clinical Trial; Concurrent Disorders; Depression; Mental Health; Mitochondrial Dna; Mitochondrial Dysfunction; Oxidative Stress; Public Health
Abstract
Since recreational cannabis use was legalized in 2018, its prevalence among people with major depressive disorder (MDD) has risen, despite evidence that cannabis may worsen depression outcomes. Previous research from our laboratory has shown that 28 days of biochemically verified cannabis abstinence improves depressive and select neurocognitive symptoms in co-occurring MDD and cannabis use disorder (CUD); however, the mechanisms underlying this relationship are unclear. Recently, mitochondrial dysfunction has been implicated in depression, with evidence of elevated circulating cell-free mitochondrial DNA (ccf-mtDNA) in MDD. Mitochondria play critical roles in neurotransmission, mood, and cognition, and their disruption may worsen depressive symptoms. Critically, cannabis is also believed to impair mitochondrial function, yet little is known about the effects of cannabis on mitochondria in MDD. To address this gap, the proposed study will investigate the effects of extended cannabis abstinence on mitochondrial function in individuals with co-occurring MDD and CUD. Participants will undergo 28 days of cannabis abstinence, confirmed by self-report with biochemical verification. Mitochondrial health will be assessed weekly during the 28-day abstinence period via urine analysis of ccf-mtDNA levels. Depressive and cognitive symptoms will also be measured throughout abstinence. We predict cannabis abstinence (compared to continued use) will result in improved mitochondrial function, as indicated by reduced urinary ccf-mtDNA levels, which will positively correlate with changes in depressive symptoms. Our findings will provide key insight into the biochemical links between depression and cannabis use and may identify new targets for the treatment of co-occurring MDD and CUD.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lonnee, Eryn P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~